Wells Fargo’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-66,920
Closed -$4M – 7273
2020
Q2
$4M Buy
66,920
+27,299
+69% +$1.69M ﹤0.01% 2686
2020
Q1
$2.35M Sell
39,621
-5,580
-12% -$325K ﹤0.01% 2857
2019
Q4
$2.48M Buy
45,201
+17,195
+61% +$642K ﹤0.01% 3181
2019
Q3
$790K Buy
28,006
+2,755
+11% +$101K ﹤0.01% 4026
2019
Q2
$838K Buy
25,251
+14,248
+129% +$445K ﹤0.01% 4003
2019
Q1
$375K Buy
11,003
+533
+5% +$17K ﹤0.01% 4503
2018
Q4
$287K Buy
10,470
+10,370
+10,370% +$267K ﹤0.01% 4701
2018
Q3
$3K Buy
+100
New +$2.82K ﹤0.01% 6206

Other funds holding PRNB

Wells Fargo's PRNB Position: Q3 2020 in Review

Wells Fargo sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 66,920 shares — an estimated $4M sold.

Wells Fargo first reported a position in PRNB in Q3 2018 and held it in 8 quarters. The position peaked at $4M in Q2 2020. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • Wells Fargo reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Wells Fargo sold 66,920 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $4M.
  • Wells Fargo first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • Wells Fargo's Principia Biopharma Inc. Common Stock position peaked at $4M in Q2 2020.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on Wells Fargo's 13F filing for Q3 2020, filed 5 Nov 2020.